Egyszerű nézet

dc.contributor.author Munkácsy, Gyöngyi
dc.contributor.author Abdul-Ghani R
dc.contributor.author Mihály, Zsuzsanna
dc.contributor.author Tegze, Bálint
dc.contributor.author Tchernitsa
dc.contributor.author Surowiak P
dc.contributor.author Schafer R
dc.contributor.author Győrffy, Balázs
dc.date.accessioned 2018-07-19T07:15:12Z
dc.date.available 2018-07-19T07:15:12Z
dc.date.issued 2010
dc.identifier 75549086500
dc.identifier.citation pagination=361-368; journalVolume=102; journalIssueNumber=2; journalTitle=BRITISH JOURNAL OF CANCER;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/5934
dc.identifier.uri doi:10.1038/sj.bjc.6605478
dc.description.abstract BACKGROUND: To date individual markers have failed to correctly predict resistance against anticancer agents in breast cancer. We used gene expression patterns attributable to chemotherapy-resistant cells to detect potential new biomarkers related to anthracycline resistance. One of the genes, PSMB7, was selected for further functional studies and clinical validation. METHODS: We contrasted the expression profiles of four pairs of different human tumour cell lines and of their counterparts resistant to doxorubicin. Observed overexpression of PSMB7 in resistant cell lines was validated by immunohistochemistry. To examine its function in chemoresistance, we silenced the gene by RNA interference (RNAi) in doxorubicin-resistant MCF-7 breast cancer cells, then cell vitality was measured after doxorubicin treatment. Microarray gene expression from GEO raw microarray samples with available progression-free survival data was downloaded, and expression of PSMB7 was used for grouping samples. RESULTS: After doxorubicin treatment, 79.8+/-13.3% of resistant cells survived. Silencing of PSMB7 in resistant cells decreased survival to 31.8+/-6.4% (P>0.001). A similar effect was observed after paclitaxel treatment. In 1592 microarray samples, the patients with high PSMB7 expression had a significantly shorter survival than the patients with low expression (P<0.001). CONCLUSION: Our findings suggest that high PSMB7 expression is an unfavourable prognostic marker in breast cancer.
dc.relation.ispartof urn:issn:0007-0920
dc.title PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer
dc.type Journal Article
dc.date.updated 2018-07-18T12:44:27Z
dc.language.rfc3066 en
dc.identifier.mtmt 1436959
dc.identifier.wos 000273728500016
dc.identifier.pubmed 20010949
dc.contributor.department SE/AOK/K/ISZGYK/MTA-SE Gyermekgyógyászati és Nephrológiai Kutatócsoport
dc.contributor.department SE/AOK/K/I. Sz. Gyermekgyógyászati Klinika
dc.contributor.institution Semmelweis Egyetem


Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.

Megtekintés/Megnyitás

Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet